Splicing modifier built to address SMA due to mutations in chromosome 5q that bring about survival motor neuron (SMN) protein deficiency. Evrysdi is administered daily in the home in liquid variety by mouth or by feeding tube. Risdiplam, an SMN2 splicing modifier, is at this time the only orally administered https://jimmyp530glp3.wikirecognition.com/user